Veramarx 20logo
14c671a0 5a50 490b b835 bf44cbf5e6db

Veramarx, Inc.

Veramarx developed the first early stage test for Lyme disease with > 90% accuracy versus current tests with 0% accuracy at the early stage.

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Boston, MA, US
  • Currency USD
  • Founded January 2012
  • Employees 2
  • Incorporation Type C-corp
  • Website

Company Summary

Veramarx has developed a multi-analyte, algorithm based diagnostic test for early stage Lyme disease.  This is a large, fast growing market where current diagnostic methods are inadequate.  The current test has 40% accuracy.  Veramarx recently completed a third validation study demonstrating 90% accuracy. Reimbursement, rapid adoption and compelling health economics have been established by gathering input from industry experts and clinicians.  


  • Whitney 20head 20shot 20copy
    Founder & Executive Chairman

    Mr. Richards was the CEO of Pop n’ Shake Development from 2002 to 2009. He was also the CEO & General Manager from 2004 to 2011 of Aboca USA, Inc. He was a senior equity trader and a member of an investment advisory board for Westpeak Investment Advisors, with over $9 billion under management. He also worked for Credit Suisse First Boston and Twenty-First Securities in New York City. Mr. Richards has an MBA and undergraduate degree in Accounting.

  • 3719fbd7 04fc 4c19 a5d2 d5c90478080b
    CEO upon closing series A round

    Mr. Macdonald has a strong track record of success with more than 25 years of international experience developing and commercializing clinical diagnostic products and laboratory services. Mr. Macdonald has served in CEO and COO roles for over 20 years, most recently as the CEO at Agendia, and formerly as a Division President, COO and Vice President at Quest Diagnostics.

Previous Investors